The complement system in COVID-19: friend and foe?
- PMID: 32554923
- PMCID: PMC7455060
- DOI: 10.1172/jci.insight.140711
The complement system in COVID-19: friend and foe?
Abstract
Coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in a global pandemic and a disruptive health crisis. COVID-19-related morbidity and mortality have been attributed to an exaggerated immune response. The role of complement activation and its contribution to illness severity is being increasingly recognized. Here, we summarize current knowledge about the interaction of coronaviruses with the complement system. We posit that (a) coronaviruses activate multiple complement pathways; (b) severe COVID-19 clinical features often resemble complementopathies; (c) the combined effects of complement activation, dysregulated neutrophilia, endothelial injury, and hypercoagulability appear to be intertwined to drive the severe features of COVID-19; (d) a subset of patients with COVID-19 may have a genetic predisposition associated with complement dysregulation; and (e) these observations create a basis for clinical trials of complement inhibitors in life-threatening illness.
Trial registration: ClinicalTrials.gov NCT04369469.
Conflict of interest statement
Figures


Similar articles
-
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection.Nat Med. 2020 Oct;26(10):1609-1615. doi: 10.1038/s41591-020-1021-2. Epub 2020 Aug 3. Nat Med. 2020. PMID: 32747830 Free PMC article.
-
Severe COVID-19: what have we learned with the immunopathogenesis?Adv Rheumatol. 2020 Sep 22;60(1):50. doi: 10.1186/s42358-020-00151-7. Adv Rheumatol. 2020. PMID: 32962761 Free PMC article.
-
Neutrophils and Contact Activation of Coagulation as Potential Drivers of COVID-19.Circulation. 2020 Nov 3;142(18):1787-1790. doi: 10.1161/CIRCULATIONAHA.120.050656. Epub 2020 Sep 18. Circulation. 2020. PMID: 32946302 Free PMC article. No abstract available.
-
Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):25018-25025. doi: 10.1073/pnas.2010540117. Epub 2020 Sep 17. Proc Natl Acad Sci U S A. 2020. PMID: 32943538 Free PMC article.
-
COVID-19: Complement, Coagulation, and Collateral Damage.J Immunol. 2020 Sep 15;205(6):1488-1495. doi: 10.4049/jimmunol.2000644. Epub 2020 Jul 22. J Immunol. 2020. PMID: 32699160 Free PMC article. Review.
Cited by
-
Editorial: COVID-19 immunology and organ transplantation.Curr Opin Organ Transplant. 2021 Apr 1;26(2):258-265. doi: 10.1097/MOT.0000000000000862. Curr Opin Organ Transplant. 2021. PMID: 33651004 Free PMC article.
-
New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?Vaccines (Basel). 2022 Sep 25;10(10):1607. doi: 10.3390/vaccines10101607. Vaccines (Basel). 2022. PMID: 36298472 Free PMC article. Review.
-
Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients.Front Immunol. 2021 May 31;12:666163. doi: 10.3389/fimmu.2021.666163. eCollection 2021. Front Immunol. 2021. PMID: 34135895 Free PMC article.
-
Development and validation of a machine learning-based prediction model for near-term in-hospital mortality among patients with COVID-19.BMJ Support Palliat Care. 2020 Sep 22:bmjspcare-2020-002602. doi: 10.1136/bmjspcare-2020-002602. Online ahead of print. BMJ Support Palliat Care. 2020. PMID: 32963059 Free PMC article.
-
Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2.Front Immunol. 2022 Mar 24;13:824378. doi: 10.3389/fimmu.2022.824378. eCollection 2022. Front Immunol. 2022. PMID: 35401544 Free PMC article.
References
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous